Generative AI in Pharmaceutical Regulatory Affairs: Uses, Benefits, Risks and Future

Pharmaceutical regulatory affairs has always been a document-intensive and information-heavy function.

Regulatory professionals routinely work with CTD/eCTD dossiers, guidelines, assessment reports, deficiency letters, product information, variations, renewals, safety updates, regulatory correspondence, labeling documents, submission trackers, and country-specific requirements.

A regulatory affairs professional may spend several hours searching a guideline just to answer one question:

“What information is required for this type of variation in this market?”

Now imagine asking an AI assistant the same question and receiving a structured answer within seconds, together with the relevant source documents, applicable sections, and a draft response.

That is where Generative Artificial Intelligence (GenAI) is becoming increasingly relevant to pharmaceutical regulatory affairs.

Generative AI can summarize documents, compare regulatory requirements, identify differences between versions, draft content, extract information, classify regulatory correspondence, and help regulatory teams navigate large volumes of information.

Importantly, however, AI should not simply be viewed as a machine that replaces the Regulatory Affairs professional. Current regulatory thinking emphasizes human oversight, risk-based use, data governance, defined context of use, documentation, and ongoing lifecycle management. FDA and EMA have published principles addressing responsible AI use in drug development, while FDA has also been actively evaluating large language models and AI-supported regulatory review.

So, what does Generative AI actually mean for pharmaceutical Regulatory Affairs?

ALSO READ: CTD vs. eCTD Submission Formats

What Is Generative AI?

Generative AI is a type of artificial intelligence that can create new content based on patterns learned from large datasets.

Unlike traditional software, which generally follows explicitly programmed rules, a generative AI system can produce:

• Text
• Summaries
• Tables
• Draft documents
• Translations
• Comparisons
• Structured answers
• Data classifications
• Question-and-answer responses

Examples include large language models (LLMs) and AI assistants capable of processing regulatory documents.

For Regulatory Affairs, this means an AI system can potentially read hundreds of pages of guidelines, dossiers, assessment reports, or correspondence and help the user identify the information that matters.

The key word is help.

The AI output should be treated as an input to professional review rather than automatically accepted as a regulatory conclusion.

Why Is Generative AI Important for Pharmaceutical Regulatory Affairs?

Regulatory Affairs faces three major challenges:

1. Huge volumes of information

Regulatory professionals may need to monitor information from multiple health authorities, pharmacopoeias, ICH, regional regulatory networks, and country-specific legislation.

2. Repetitive documentation

Many activities involve repetitive document review, comparison, extraction, formatting, and drafting.

3. Increasing regulatory complexity

Different countries may require different formats, administrative documents, labeling requirements, timelines, and supporting data.

Generative AI has the potential to reduce the amount of manual searching and repetitive drafting so regulatory professionals can focus more heavily on scientific interpretation, regulatory strategy, risk assessment, and communication with authorities.

This is not merely theoretical. FDA has publicly described its work evaluating large language models for regulatory review tasks such as literature screening, adverse-reaction detection from labeling, FAERS report deduplication, and document-question answering.

In May 2026, FDA also announced an upgraded internal AI capability, Elsa 4.0, alongside consolidation of agency submission and data sources intended to enable broader AI-supported workflows.

Major Applications of Generative AI in Regulatory Affairs

1. Regulatory Intelligence

Regulatory intelligence is one of the most promising applications.

A regulatory professional may need to determine:

• Has a health authority changed its guideline?
• When did the change become effective?
• What sections were revised?
• Does the change affect our product?
• What action should the company take?

An AI system can help compare old and new documents and produce a structured summary.

The final interpretation still requires a qualified Regulatory Affairs professional.

2. CTD and eCTD Dossier Preparation

Generative AI can assist in preparing and reviewing regulatory dossiers.

Potential applications include:

• Summarizing Module 3 information
• Reviewing Module 2 summaries
• Checking consistency between sections
• Identifying missing information
• Comparing manufacturing descriptions
• Checking terminology
• Finding discrepancies in strengths, batch sizes, specifications, or shelf life
• Preparing document checklists

For example, suppose the approved product information states:

Shelf life: 24 months

but another dossier section states:

Shelf life: 36 months

AI can potentially flag this inconsistency for human review.

This type of application can be particularly useful when Regulatory Affairs teams manage many products across several markets.

3. Regulatory Submission Gap Assessment

One of the most practical applications is submission gap analysis.

Suppose a company wants to register a generic product in a new country.

The Regulatory Affairs professional provides the AI assistant with:

• Applicable national guideline
• CTD checklist
• Existing dossier index
• Previous regulatory correspondence
• Product information

The AI can organize the requirements into a table:

Requirement	Available?	Gap	Recommended Action
Administrative forms	Yes	None	Verify latest version
Manufacturing information	Yes	Minor	Update site details
Stability data	Yes	Potential gap	Confirm required duration
GMP certificate	Yes	None	Verify validity
Bioequivalence report	Yes	None	Cross-check product strength

This does not replace the official regulatory assessment, but it can make the initial gap analysis considerably faster.

4. Drafting Responses to Regulatory Queries

Regulatory authorities may send multiple questions during dossier evaluation.

For example:

“Please provide justification for the proposed dissolution acceptance criterion.”

A regulatory professional can provide the AI with the relevant technical information, approved method, supporting literature, and internal scientific position.

The AI can then prepare a first draft response.

The Regulatory Affairs team can revise it, add scientific evidence, verify references, and obtain appropriate subject-matter approval.

This approach changes the role of AI from an "answer generator" to a drafting assistant.

However, this area requires particular caution.

In June 2026, the UK MHRA Inspectorate publicly discussed cases where AI-generated GxP inspection responses contained references to guidance that did not exist, inappropriate regulatory frameworks, and wording that could fail to properly address serious deficiencies. MHRA emphasized that AI can support responses, but inappropriate or unverified AI-generated content creates regulatory risk.

That is a very practical warning for Regulatory Affairs teams.

ALSO READ: Registration and Approval Process of Medical Device in Japan

5. Product Labeling and Regulatory Information

Generative AI can help review product information, including:

• SmPC
• Package leaflet
• USPI
• Patient information
• Safety information
• Contraindications
• Warnings
• Dosing instructions

AI can compare multiple versions and identify differences.

For example:

Version 4: “Store below 25°C.”

Version 5: “Store below 30°C.”

An AI comparison tool could highlight the change and ask the Regulatory Affairs professional to determine whether the difference is intentional and properly approved.

EMA's reflection paper on AI in the medicinal product lifecycle specifically discusses applications at the marketing-authorization stage, including tools that may assist with drafting, compiling, translating, or reviewing product information.

6. Regulatory Correspondence Management

A multinational company may receive hundreds of regulatory emails and letters.

AI can classify communications into categories such as:

• New registration
• Variation
• Renewal
• Deficiency
• GMP
• Pharmacovigilance
• Labeling
• Manufacturing site
• Administrative
• Urgent action

It can then summarize each communication and extract:

Authority → Product → Request → Due Date → Responsible Person → Required Action

This can reduce the possibility of important requests being buried in email traffic.

7. Variation and Change Management

Generative AI can assist with variation assessments.

Consider a company changing:

API manufacturer

The regulatory professional may need to determine:

• Which markets are affected?
• What variation category applies?
• Which documents are required?
• Is updated stability data needed?
• Is validation data required?
• Is a GMP document needed?
• Does the change affect product information?

AI can help organize the requirements by country.

The final regulatory classification should still be confirmed against the current applicable regulations and guidance.

ALSO READ: Regulatory Requirements for Drug Master File (DMF) Submission in the United States

8. Regulatory Translation

Multinational pharmaceutical companies frequently translate:

• Regulatory letters
• Product information
• Submission documents
• Administrative forms
• Agency questions
• Responses

Generative AI can accelerate initial translation and help maintain consistent terminology.

However, regulatory translation is not ordinary translation.

A small change in wording can affect the meaning of:

• Dosage
• Contraindication
• Warning
• Route of administration
• Storage condition
• Legal responsibility

Therefore, regulatory translation should include appropriate human linguistic and subject-matter review.

Benefits of Generative AI in Regulatory Affairs

The main benefits can be summarized as:

1. Faster document review: AI can process large amounts of text far more rapidly than manual review.
2. Improved consistency: It can help identify inconsistencies between documents.
3. Better regulatory intelligence: AI can organize large amounts of regulatory information into usable summaries.
4. Reduced repetitive work: Routine drafting and comparison tasks can be accelerated.
5. Better knowledge access: Experienced professionals can search large internal document libraries more efficiently.
6. Faster response preparation: Draft responses to regulatory questions can be created faster, leaving more time for scientific review.

The broader objective is not simply to make regulatory departments "faster." It is to move skilled professionals away from repetitive information processing and toward higher-value regulatory decision-making.

What Are the Risks of Generative AI in Regulatory Affairs?

Generative AI also introduces significant risks.

1. Hallucination

AI may generate information that sounds convincing but is incorrect.

It may invent:

• Guidance documents
• Regulatory requirements
• Citations
• Legal provisions
• Deadlines
• Scientific references

The MHRA's 2026 discussion of AI-generated GxP inspection responses provides a real regulatory example of this problem.

2. Confidentiality

Pharmaceutical companies handle confidential information such as:

• Product dossiers
• Clinical data
• Formulations
• Manufacturing processes
• Commercial strategies
• Regulatory correspondence

Organizations must control where such data is processed and whether information is retained or used by external services.

A public consumer AI tool should not automatically be treated as an appropriate repository for confidential regulatory information.

3. Data Integrity

AI-assisted workflows must not undermine:

• Attribution
• Traceability
• Version control
• Auditability
• Record retention
• Review and approval processes

An organization should be able to determine:

• What information was provided to the AI?
• What did the AI generate?
• Who reviewed it?
• What changes were made?
• Who approved the final document?

4. Outdated Information

A generative AI model may not automatically know the latest regulatory requirement.

Regulatory guidance changes frequently.

Therefore, an AI answer should be verified against the current official source before being used in regulatory decision-making.

ALSO READ: FDA Audit Preparation

How Should Pharmaceutical Companies Govern Generative AI?

A pharmaceutical company should not simply give employees access to an AI tool and say:

“Use it responsibly.”

A structured governance framework is much stronger.

The company should define:

1. Approved Use Cases

Examples:

• Document summarization
• Regulatory intelligence
• Drafting
• Document comparison
• Internal knowledge search

2. Restricted Use Cases

For example:

• Direct regulatory decisions without human review
• Final submission approval
• Automatic interpretation of ambiguous regulations

3. Prohibited Use Cases

Examples may include uploading confidential information into unauthorized external AI systems or using AI-generated content without appropriate verification.

4. Human Review

The riskier the activity, the stronger the human review should be.

FDA's 2025 draft guidance on AI supporting regulatory decision-making proposed a risk-based credibility assessment framework tied to the specific context of use. The document is a draft and explicitly says it is not for implementation, but it illustrates the direction of regulatory thinking around risk-based AI governance.

FDA and EMA have also published ten guiding principles for good AI practice in drug development, emphasizing human-centric design, risk-based approaches, context of use, multidisciplinary expertise, data governance, performance assessment, lifecycle management, and clear documentation.

The Future of Generative AI in Pharmaceutical Regulatory Affairs

The future is unlikely to be simply:

Human Regulatory Affairs → AI replaces human

A more realistic model is:

Regulatory Professional + Enterprise Data + Generative AI + Human Oversight

Imagine a future regulatory workspace where an AI assistant continuously monitors approved regulatory sources and internal product information.

A Regulatory Affairs professional could ask:

“Which current requirements may affect our registered products because of this new guideline?”

The system could identify potentially affected products, summarize the relevant changes, identify supporting documents, and create an assessment list.

The professional would then review and approve the conclusions.

This type of human-AI collaboration is already being explored by regulators themselves. FDA has described AI work involving large language models, document analysis, literature screening, adverse-event information, and regulatory-review support.

References

1. U.S. FDA. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products — Draft Guidance, January 2025.
2. U.S. FDA. Guiding Principles of Good AI Practice in Drug Development.
3. European Medicines Agency. Reflection paper on the use of Artificial Intelligence in the medicinal product lifecycle, current version adopted in 2024.
4. U.S. FDA. FDA Grand Rounds – Adopting Large Language Models for Regulatory Review, April 10, 2025.
5. U.S. FDA. FDA Expands AI Capabilities and Completes Data Platform Consolidation, May 6, 2026.
6. U.S. FDA. FY 2025 GDUFA Science and Research Report — AI/LLM-supported regulatory workflow research.
7. UK MHRA Inspectorate. Use of AI for GXP inspection responses: setting standards without stifling innovation, June 29, 2026.

ALSO READ: FDA Releases Draft Guidance on Quality Management System (QMS) Requirements for Premarket Submissions — October 2025